← All stories
Markets
Key HIV stat over 70% leaves BofA siding with Gilead
Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fresh reasons to stay bullish heading into…
Covered by 1 outlet
All coverage · 1 article